• AAPL 166.09
  • TSLA 149.65
  • AMZN 177.64
  • MSFT 403.6728
  • INTC 34.8
  • EURUSD 1.0675
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NYSE /
  3. AMRX.NYSE

Amneal Pharmaceuticals Inc. Class A Common Stock (AMRX NYSE) stock market data APIs

$5.46 0.1(1.9%) as of April 18, 2024

Amneal Pharmaceuticals Inc. Class A Common Stock Financial Data Overview

5.36
5.46
-
5.47
5.34
1.58-6.46
1 654 M
309 M
2 394 M
0.14
1.354
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'AMRX',
Type: 'Common Stock',
Name: 'Amneal Pharmaceuticals Inc. Class A Common Stock',
Exchange: 'NYSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00462PGG0',
ISIN: NULL,
CUSIP: NULL,
CIK: '1723128',
EmployerIdNumber: '32-0546926',
FiscalYearEnd: 'December',
IPODate: '2009-01-15',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Amneal Pharmaceuticals Inc. Class A Common Stock Fundamental Data is available in our Financial Data APIs

  • Net Revenue 2 394 M
  • EBITDA 501 M
  • Earnings Per Share -0.48
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Amneal Pharmaceuticals Inc. Class A Common Stock Earnings via APIs

  • Latest Release 2024-03-01
  • EPS/Forecast 0.09

Get Amneal Pharmaceuticals Inc. Class A Common Stock End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Amneal Pharmaceuticals Inc. Class A Common Stock latest news via APIs

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Novel 505(b)(2) presentation of a key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma, does not require reconstitution, dilution, or refrigeration Am...

Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week

When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your ...
Do you have any questions?
support@eodhistoricaldata.com